Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
about
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case reportDrug interactions in childhood cancer.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathyHas the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Treatment considerations in pulmonary coccidioidomycosis.Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation.Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients.Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients.A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study.A case of treatment with voriconazole for chronic progressive pulmonary aspergillosis in a patient receiving tacrolimus for dermatomyositis-associated interstitial lung disease.Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring.Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL.Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study.Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients.Tacrolimus Dose Modification in Hematopoietic Cell Transplant Recipients Following a Change in Therapy from Fluconazole to Voriconazole
P2860
Q33665780-B60A23D3-DF42-4DB1-994C-D4B2E19A6392Q36898141-35D7C485-26F6-40D1-9D1D-1B619B3F92C6Q36927577-206D98CD-6308-435D-92EF-959A16E3D73BQ37303616-E8B1FC8F-E12B-4330-A81A-10647B1EA3F3Q37904672-52630EF3-98DD-4CD6-A11D-83FBE1517A98Q37945308-9864DF02-0AC5-4D48-B781-C6B6868FF9B1Q38284468-5088B6F8-8511-4C7C-B709-F8E810CE1E28Q38820536-928646BE-76E6-4683-94AA-BECC3E4325B9Q38838088-8A571C0A-20E2-4CFE-8623-2CC04FE16376Q39443748-CF7DD6AC-9AD3-46AE-B35F-D0D54549E92CQ39479653-D7A82874-E32D-4683-B794-E8E1F4C35229Q39634880-0958936E-1F37-420B-B4E6-EAA4647E1700Q40171742-EB68EE65-9934-4B58-A51A-CB63B84CC36CQ41392620-3B3441AF-DBB1-402D-978D-8C01EF1C946AQ41700108-C3F34458-40BB-4CA8-A245-62488A30138BQ42222406-AD5AD08F-6526-4FC6-9466-5081D3A6C1B1Q42517186-771A8892-59EF-4EA3-92A6-96A09F2C2AA5Q43125617-64547EBA-15C6-4B5F-89C3-98E1E50C048BQ43228483-D4AE75A2-A7CF-43FC-A251-27AA646E81C6Q43246066-9A97E5A6-1C00-47F2-A407-A7FCBE7BFB2AQ44133007-9A8C24B0-B58B-419D-9860-C4F6927CA0DEQ44362330-5EBB3AD1-D376-4677-A2DF-32220FC04EA8Q45176557-B951818B-F695-4E17-959D-91283984B565Q53139996-AEF22DF7-DAD8-4FC8-AA34-F041FFE020CAQ53477089-3074980E-8661-4450-AB03-190A039E79C5Q58993760-9EFC3FB4-A75A-4054-A8AA-AB75A66F56EC
P2860
Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Drug interaction between voric ...... em cell transplant recipients.
@en
Drug interaction between voric ...... em cell transplant recipients.
@nl
type
label
Drug interaction between voric ...... em cell transplant recipients.
@en
Drug interaction between voric ...... em cell transplant recipients.
@nl
prefLabel
Drug interaction between voric ...... em cell transplant recipients.
@en
Drug interaction between voric ...... em cell transplant recipients.
@nl
P2093
P2860
P356
P1476
Drug interaction between voric ...... em cell transplant recipients.
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2009.38
P407
P577
2009-03-09T00:00:00Z